PH issues cease and desist order against Fabunan drug for COVID-19

The Philippines’ Food and Drug Administration (FDA) has issued a cease and desist order against the Fabunan drug after a video on made its rounds on social media that the unregistered antiviral injection that was believed to be a cure against the coronavirus disease (COVID-19) was being administered in Zambales.
Department of Health (DOH) Undersecretary Maria Rosario Vergiere stated that the Fabunan antiviral injection is not yet registered and thus isn’t vetted for public safety.
“They still have not applied for CPR (certificate of product registration). They were already issued a cease and desist order by FDA, case buildup is being done already,” said Vergiere who furthered that studies regarding the drug are already being handled by the DOH.
RELATED STORY: PH to join clinical trials for COVID-19 vaccine by end of 2020
“We are studying the case already. FDA has jurisdiction when it comes to the unregistered drug or vaccine, and PRC (Professional Regulation Commission) for the practice of medicine,” added Vergiere.
Last month, Malacañang urged DFA to study the viability of the Fabunan antiviral injection if it can indeed be used to cure COVID-19 patients.
The aforementioned viral video stated that the Fabunan antiviral injection was a patented antiviral drug against dengue developed by Washington-based Filipino doctor Ruben Fabunan and that it is an “approved” drug and has been “proven to be used to treat Covid-19”, as per reports from the Philippine News Agency.
READ ON: COVID-19 vaccine tested in US shows promising results in clinical trial
FDA continues to warn the public that no such drug and/or vaccine has been licensed to date for the treatment of COVID-19.
Authorities remind and urge the public to be vigilant and avoid misinformation that might cause greater harm to their health.

Staff Report

The Filipino Times is the chronicler of stories for, of and by Filipinos all over the world, reaching more than 236 countries in readership. Any interesting story to share? Email us at [email protected]

Related Articles

Back to top button